Opinion|Videos|February 27, 2026
Supporting Patients Following Initial EGFR+ NSCLC Diagnosis
Narjust Florez, MD, and Stephanie J. McDonald, MSN, FNP-BC, AOCNP, discuss initial conversations and methods of support for patients with EGFR-mutated NSCLC.
Advertisement
Narjust Florez, MD, and Stephanie J. McDonald, MSN, FNP-BC, AOCNP, review key considerations when counseling patients after a new diagnosis of EGFR-mutated non–small cell lung cancer. Florez discusses the importance of setting expectations regarding prognosis, treatment duration, and potential toxicities associated with targeted therapies. McDonald outlines supportive strategies, including education resources and psychosocial support, to help patients navigate complex treatment decisions early in their care journey.
Advertisement
Related to this article
The FDA approved pirtobrutinib for untreated chronic lymphocytic leukemia, granted priority review to elinzanetant for breast cancer hot flashes, and more.
The 2026 amendment adds 40 new recommendations, including active surveillance, office-based treatment, and chemoablation for select recurrent low-grade disease.
The FDA has approved pirtobrutinib for the treatment of adult patients with previously untreated CLL or SLL harboring no known 17p deletion.
By finding a way to attack the most important human oncogene, KRAS, the UCSF chemical biologist launched a new era in cancer treatment.
TRE-515 earned fast track status in combination with KRAS inhibitors for G12C-mutated NSCLC after anti–PD-(L)1 therapy and platinum-based chemotherapy.
An NDA for zipalertinib in EGFR exon 20 insertion–positive NSCLC is being supported by phase 3 REZILIENT3 data.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Aglatimagene besadenovec plus EBRT was linked to a 41% lower risk of prostate cancer recurrence or death, alongside durable immune activity.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL
2
The OncFive: Top Oncology Articles for the Week of 9/27/2026
3
FDA Grants Fast Track Designation to TRE-515 Plus KRAS Inhibitors in Pretreated KRAS G12C+ NSCLC
4
AUA Releases Guideline Amendment for NMIBC
5